Ipamorelin

Ipamorelin is a synthetic pentapeptide developed in the late 1990s by researchers at Novo Nordisk during a search for a cleaner growth hormone secretagogue. It belongs to the growth hormone releasing peptide (GHRP) family and works by imitating ghrelin, a gut hormone that signals hunger and also triggers growth hormone release. Rather than following the natural pathway driven by growth hormone releasing hormone (GHRH), it acts on the ghrelin receptor, also called the growth hormone secretagogue receptor, in the pituitary and hypothalamus. It was designed to be more selective than earlier GHRPs such as GHRP-6 and hexarelin, which tended to also raise cortisol, prolactin, and appetite. Ipamorelin was never brought to market as an approved drug and instead moved into research supply and, more recently, the wellness and peptide-clinic space. Much of the primary characterization still traces back to that early work rather than a broad body of independent human trials.

People most often look into ipamorelin for the effects commonly attributed to raising growth hormone: better sleep quality, faster recovery, and gradual shifts in body composition toward more lean mass and less fat. It is almost always discussed alongside CJC-1295, and the two are paired so often that “CJC-1295 and ipamorelin” is treated as a single classic stack. The reasoning behind the pairing is that the two act on different systems, so combining a GHRH analog with a ghrelin-mimic is thought to produce a larger combined growth hormone pulse than either compound alone. Some users report that its selectivity makes it feel gentler than older secretagogues, with less of the intense hunger associated with GHRP-6. Most of these reported benefits come from user experience and mechanism reasoning rather than large controlled trials.

What sets ipamorelin apart is that it stimulates growth hormone through the ghrelin receptor rather than the GHRH receptor, so it works on a completely separate arm of the same system. Its defining feature is selectivity: at typical signaling levels it prompts the pituitary to release growth hormone with minimal knock-on effect on cortisol and prolactin, which were problematic with earlier peptides in its class. Because it mimics ghrelin, the signal is sensitive to food state, and eating, which raises insulin and blunts ghrelin activity, can dampen the response, which is why fasted timing is often emphasized. One frequently cited observation is that repeated dosing over roughly three weeks did not appear to desensitize the pituitary, whereas GHRH-based peptides can lose effect as their receptors down-regulate with daily use. The release it drives is pulsatile rather than a sustained flood, which is generally viewed as closer to normal physiology.

Ipamorelin is a peptide, so it is not meaningfully active by mouth and is described in reported protocols as a subcutaneous injection, typically a small volume into the fat under the skin. Because its action mimics ghrelin, discussions of timing tend to stress dosing on an empty stomach, often before bed or between meals, so that food and insulin do not blunt the growth hormone pulse. When it is stacked with CJC-1295, the two are commonly reconstituted and drawn together in the same injection. It acts systemically through the pituitary rather than at a local site, so where it is injected is mostly a matter of comfort rather than targeting. The specific doses, frequencies, and cycle lengths repeated online are not backed by clinical dosing studies, and several clinicians point out that confident-sounding numbers are largely extrapolated rather than established.

The evidence base for ipamorelin is thin and weighted toward early pharmacology and animal work rather than large human outcome trials. Its selectivity, its action on the ghrelin receptor, and the apparent lack of pituitary desensitization over about 21 days are reasonably well described in that early research, but robust long-term human data on the body composition, recovery, and anti-aging benefits people seek is largely absent. Ipamorelin itself was never approved for human use, and closely related compounds such as CJC-1295 without DAC have essentially no formal studies, so much of the practical guidance around this stack rests on mechanism reasoning and anecdote. Clinicians who cover it also raise a broader caution: pushing growth hormone and IGF-1 too high carries theoretical risks, including insulin resistance, and animal models tend to associate lower growth hormone signaling with longer lifespan. In short, the mechanism is interesting and fairly well understood, but the human evidence for the promised results is not settled.

Ipamorelin has no FDA approval for any human indication and is not a licensed medicine, so it circulates largely as a research chemical and through compounding pharmacies and wellness clinics. Its regulatory footing has been tightening, as growth hormone secretagogues have drawn increased scrutiny over compounding, and the rules in this area are changing quickly, so availability through legitimate channels can shift. In sport, growth hormone secretagogues including ghrelin-receptor agonists like ipamorelin are prohibited by the World Anti-Doping Agency at all times, meaning it is banned for tested athletes. It is sometimes labeled or sold simply as a GHRP or growth hormone secretagogue, and it is most often encountered bundled with CJC-1295. Online availability is separate from approval.